Picture of Appili Therapeutics logo

APLI Appili Therapeutics Share Price

0.000.00%
ca flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapMomentum Trap

Momentum

Relative Strength (%)
1m+28.16%
3m+44.26%
6m+0.79%
1yr+20.82%
Volume Change (%)
10d/3m+290.05%
Price vs... (%)
52w High-43.75%
50d MA+36.99%
200d MA+12.46%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capitaln/a
Return on Equityn/a
Operating Margin-684.02%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Mar 202431st Mar 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Appili Therapeutics EPS forecast chart

Profile Summary

Appili Therapeutics Inc. is a Canada-based biopharmaceutical company. The Company is advancing a diverse range of anti-infectives, including a vaccine candidate to eliminate a serious biological weapon threat, a topical antiparasitic for the treatment of a disfiguring disease, and a novel easy to use, liquid oral formulation targeting parasitic and anaerobic infections. The Company’s anti-infective product development portfolio includes three programs, including ATI-1701, ATI-1801 and ATI-1501. ATI-1701 is a novel, live-attenuated vaccine for Francisella tularensis (F. tularensis). ATI-1801 is a novel topical formulation of paromomycin (15% w/w) under advanced clinical development for the treatment of cutaneous leishmaniasis, a disfiguring infection of the skin that affects hundreds of thousands of people around the world annually. The ATI-1501 is a taste-masked liquid oral suspension formulation of the antibiotic metronidazole.

Directors

Last Annual
March 31st, 2023
Last Interim
December 31st, 2023
Incorporated
May 7th, 2015
Public Since
June 25th, 2019
No. of Employees
8
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
ca flag iconToronto Stock Exchange
Shares in Issue
121,266,120

APLI Share Price Performance

Upcoming Events for APLI

Q4 2024 Appili Therapeutics Inc Earnings Release

Q1 2025 Appili Therapeutics Inc Earnings Release

Appili Therapeutics Inc Annual Shareholders Meeting

Similar to APLI

Picture of AEterna Zentaris logo

AEterna Zentaris

ca flag iconToronto Stock Exchange

Picture of Antibe Therapeutics(Pre-Merger) logo

Antibe Therapeutics(Pre-Merger)

ca flag iconToronto Stock Exchange

Picture of Aptose Biosciences logo

Aptose Biosciences

ca flag iconToronto Stock Exchange

Picture of Avicanna logo

Avicanna

ca flag iconToronto Stock Exchange

Picture of Briacell Therapeutics logo

Briacell Therapeutics

ca flag iconToronto Stock Exchange

FAQ